Molecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA.
Quant Imaging Med Surg. 2012 Sep;2(3):151-62. doi: 10.3978/j.issn.2223-4292.2012.08.04.
Type 1 diabetes mellitus results in impaired insulin production by pancreatic islets due to autoimmunity. Islet transplantation has recently emerged as a promising treatment for this disease. To visualize and monitor endogenous and transplanted islets, non-invasive strategies are currently being developed. These include strategies for in vivo magnetic resonance imaging of microvascular changes during diabetes development, tracking the recruitment of diabetogenic T cells to the pancreas, and imaging of endogenous and transplanted islet mass. The combination of MR imaging agents with therapy is a novel state-of-the-art theranostic approach that has a tremendous potential for type 1 diabetes management. Though still in its infancy, theranostic MR imaging has shown certain encouraging progress. Here we provide an overview of the latest accomplishments in this area as it applies to changes in islet vasculature during diabetes development, monitoring autoimmune attack mediated by T cells, and imaging of transplanted islets. Future challenges and opportunities in the area of theranostic MRI are discussed as well.
1 型糖尿病由于自身免疫导致胰岛产生胰岛素的能力受损。胰岛移植最近已成为治疗这种疾病的一种有前途的方法。为了可视化和监测内源性和移植的胰岛,目前正在开发非侵入性策略。这些策略包括在糖尿病发展过程中进行体内磁共振成像微血管变化、追踪致糖尿病 T 细胞向胰腺募集,以及成像内源性和移植胰岛质量。MR 成像剂与治疗相结合是一种新的治疗方法,对 1 型糖尿病的管理具有巨大的潜力。虽然仍处于起步阶段,但治疗性磁共振成像已经显示出某些令人鼓舞的进展。在这里,我们提供了该领域最新进展的概述,适用于糖尿病发展过程中胰岛血管变化、监测 T 细胞介导的自身免疫攻击以及移植胰岛成像。还讨论了治疗性 MRI 领域的未来挑战和机遇。